Sobi to Present Phase 3 Gout Drug Study Results
The pharmaceutical company will share new trial data on November 11, 2026, at the ACR Convergence conference.
Updated on Oct. 29, 2026 in Arthritis
Live Poll
Do you trust that new medical innovations are effectively improving treatment options for chronic conditions?
Sobi is set to present Phase 3 clinical study results for the experimental gout drug pozdeutinurad on November 11, 2026. The findings from the REDUCE-2 study demonstrate the drug's effectiveness in reducing serum urate levels in patients.
Why it matters
Managing uncontrolled gout is critical for patients, as lowering serum urate levels is necessary to prevent long-term damage to joints and surrounding tissues.
In the Phase 3 REDUCE-2 trial of 811 patients, the 75 mg dose achieved success in 69.2 percent of participants, while the 50 mg dose reached the 6 mg/dL target in 56.6 percent compared to 8.1 percent for the placebo.
The players
Sobi
This international biopharmaceutical company focuses on developing specialized treatments for rare diseases.
ACR Convergence 2026
This is the annual scientific meeting hosted by the American College of Rheumatology to discuss advancements in the field.
The details
The double-blind study evaluated the efficacy of once-daily oral doses of pozdeutinurad over a 12-month period. Adverse events were reported in approximately 60 percent of patients across both treatment arms and the placebo group.
Timeline
Month 6: Primary endpoint assessment for serum urate levels.
Month 12: End of the study data collection period.
November 11, 2026: Late-breaking data presentation at ACR Convergence 2026.
Health Landscape
This study presentation at ACR Convergence reflects the ongoing effort in rheumatology to replace legacy gout treatments with more targeted oral therapies. These advancements aim to bridge the gap between initial diagnosis and long-term joint health maintenance.
For patients suffering from chronic gout, these results offer a potential new daily oral treatment option to manage urate levels. Further clinical guidance will depend on final regulatory approvals following these Phase 3 results.
The takeaway
Maintaining target serum urate levels below 6 mg/dL is a primary strategy for preventing the tissue damage associated with gout. Patients should consult with a rheumatologist to discuss how evolving clinical trial results may influence future treatment options.
Further reading
Learn more about new clinical developments in the Arthritis section.
Live Poll
Do you trust that new medical innovations are effectively improving treatment options for chronic conditions?
